Treatment with AstraZeneca's oral Casodex (bicalutamide) is aseffective in terms of overall survival and time-to-disease-progression as surgical or medical castration, according to trials involving patients with non-metastatic, locally-advanced prostate cancer. Furthermore, treatment with Casodex has quality of life benefits over castration, including greater maintenance of sexual interest and a reduction in the incidence of hot flushes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze